Clinical and economic benefits of bivalent Respiratory syncytial virus prefusion F (RSVpreF) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.
RSVpreF vaccination would substantially reduce the clinical and economic burden of RSV among adults in Singapore and be cost-effective under a threshold of 1 ×gross domestic product per capita per QALY gained.